Julie Burek - Jan 3, 2022 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Role
VP, Finance
Signature
/s/ Robert Hesslein, as Attorney-in-Fact for Julie Burek
Stock symbol
VYGR
Transactions as of
Jan 3, 2022
Transactions value $
-$2,434
Form type
4
Date filed
1/14/2022, 05:14 PM
Previous filing
Nov 30, 2021
Next filing
Jan 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYGR Common Stock Award $7.04K +3.06K +6.58% $2.30* 49.6K Dec 31, 2021 Direct F1
transaction VYGR Common Stock Sale -$8.67K -3.06K -6.18% $2.83 46.5K Jan 3, 2022 Direct
transaction VYGR Common Stock Sale -$811 -265 -0.57% $3.06 46.3K Jan 12, 2022 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).
F2 Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.92 to $3.22, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.